Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

246 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.
Domingo-Domenech J, Oliva C, Rovira A, Codony-Servat J, Bosch M, Filella X, Montagut C, Tapia M, Campás C, Dang L, Rolfe M, Ross JS, Gascon P, Albanell J, Mellado B. Domingo-Domenech J, et al. Among authors: rolfe m. Clin Cancer Res. 2006 Sep 15;12(18):5578-86. doi: 10.1158/1078-0432.CCR-05-2767. Clin Cancer Res. 2006. PMID: 17000695 Clinical Trial.
Anticancer antibodies.
Ross JS, Gray K, Gray GS, Worland PJ, Rolfe M. Ross JS, et al. Among authors: rolfe m. Am J Clin Pathol. 2003 Apr;119(4):472-85. doi: 10.1309/Y6LP-C0LR-726L-9DX9. Am J Clin Pathol. 2003. PMID: 12710120 Review.
Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib.
Williamson MJ, Blank JL, Bruzzese FJ, Cao Y, Daniels JS, Dick LR, Labutti J, Mazzola AM, Patil AD, Reimer CL, Solomon MS, Stirling M, Tian Y, Tsu CA, Weatherhead GS, Zhang JX, Rolfe M. Williamson MJ, et al. Among authors: rolfe m. Mol Cancer Ther. 2006 Dec;5(12):3052-61. doi: 10.1158/1535-7163.MCT-06-0185. Mol Cancer Ther. 2006. PMID: 17172407
The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.
Le Moigne R, Aftab BT, Djakovic S, Dhimolea E, Valle E, Murnane M, King EM, Soriano F, Menon MK, Wu ZY, Wong ST, Lee GJ, Yao B, Wiita AP, Lam C, Rice J, Wang J, Chesi M, Bergsagel PL, Kraus M, Driessen C, Kiss von Soly S, Yakes FM, Wustrow D, Shawver L, Zhou HJ, Martin TG 3rd, Wolf JL, Mitsiades CS, Anderson DJ, Rolfe M. Le Moigne R, et al. Among authors: rolfe m. Mol Cancer Ther. 2017 Nov;16(11):2375-2386. doi: 10.1158/1535-7163.MCT-17-0233. Epub 2017 Sep 6. Mol Cancer Ther. 2017. PMID: 28878026
Targeted therapies for cancer 2004.
Ross JS, Schenkein DP, Pietrusko R, Rolfe M, Linette GP, Stec J, Stagliano NE, Ginsburg GS, Symmans WF, Pusztai L, Hortobagyi GN. Ross JS, et al. Among authors: rolfe m. Am J Clin Pathol. 2004 Oct;122(4):598-609. doi: 10.1309/5CWP-U41A-FR1V-YM3F. Am J Clin Pathol. 2004. PMID: 15487459 Review.
Antibody-based therapeutics: focus on prostate cancer.
Ross JS, Gray KE, Webb IJ, Gray GS, Rolfe M, Schenkein DP, Nanus DM, Millowsky MI, Bander NH. Ross JS, et al. Among authors: rolfe m. Cancer Metastasis Rev. 2005 Dec;24(4):521-37. doi: 10.1007/s10555-005-6194-0. Cancer Metastasis Rev. 2005. PMID: 16408160 Review.
Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.
Kupperman E, Lee EC, Cao Y, Bannerman B, Fitzgerald M, Berger A, Yu J, Yang Y, Hales P, Bruzzese F, Liu J, Blank J, Garcia K, Tsu C, Dick L, Fleming P, Yu L, Manfredi M, Rolfe M, Bolen J. Kupperman E, et al. Among authors: rolfe m. Cancer Res. 2010 Mar 1;70(5):1970-80. doi: 10.1158/0008-5472.CAN-09-2766. Epub 2010 Feb 16. Cancer Res. 2010. PMID: 20160034
246 results